Skip to main content

Syntheses and In-Vitro Evaluation of Novel Adamantane Based γ-Secretase Inhibitors

Buy Article:

$55.00 plus tax (Refund Policy)

Abnormal processing of amyloid precursor protein (APP) by β - and γ -secretases to produce excess amyloid-β-peptide is believed to contribute to the pathophysiological cascade that results in Alzheimer’s disease. γ -Secretase inhibition or modulation therefore represents a rational approach to the prevention and/or management of AD. Here, we present the discovery and SAR of a class of novel adamantanyl sulfonamide based γ -secretase inhibitors. Activity evaluation was conducted on cell lines overexpressing APP (wild type and Swedish mutation). Our results suggest size threshold and hydrogen bond formation are necessary for inhibitory activity. There was no correlation between compound activity, Log P, and the electronic effect of substituents on the aromatic ring. These compounds possess desirable drug like properties and results of the study can guide a pharmacophore based design of γ -secretase inhibitors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: APP swedish mutation (APPswe); Alzheimer’s disease (AD); amyloid precursor protein (APP); amyloid-β-peptide (Aβ); aspartyl protease; inhibitors; intramembrane proteolytic cleavage; neurofibrillary tangles; plaques; sulfonamides; α-secretase; β-secretase; γ -secretase inhibitors

Document Type: Research Article

Affiliations: Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd Street, Philadelphia, PA, 19104, USA.

Publication date: 2012-05-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more